Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426))

Yoshihiko Sakata; Go Saito; Shinya Sakata; Yuko Oya; Motohiro Tamiya; Hidekazu Suzuki; Ryota Shibaki; Asuka Okada; Toshihide Yokoyama; Hirotaka Matsumoto; Taiichiro Otsuki; Yuki Sato; Uchida Junji; Yoko Tsukita; Megumi Inaba; Hideki Ikeda; Daisuke Arai; Hirotaka Maruyama; Satoshi Hara; Shinsuke Tsumura; Jun Morinaga; Takuro Sakagami

doi:10.1016/j.lungcan.2023.107450

Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426))

Yoshihiko Sakata, Go Saito, Shinya Sakata, Yuko Oya, Motohiro Tamiya, Hidekazu Suzuki, Ryota Shibaki, Asuka Okada, Toshihide Yokoyama, Hirotaka Matsumoto, Taiichiro Otsuki, Yuki Sato, Uchida Junji, Yoko Tsukita, Megumi Inaba, Hideki Ikeda, Daisuke Arai, Hirotaka Maruyama, Satoshi Hara, Shinsuke TsumuraJun Morinaga, Takuro Sakagami

Respiratory Medicine & Clinical Allergy

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The authors sincerely apologize for the errors; we have now corrected these errors. 1. Highlights Section: Error: “Median progression-free survival was shorter in the elderly than in the non-elderly.” Correction: “Time to treatment failure was shorter in the elderly than in the non-elderly.” 2. Abstract's Result Section: Error: “the time to treatment failure (TTF) was significantly shorter in the elderly than in the non-elderly [elderly group: median TTF, 14.0 months (95% CI: 0.98–1.50); non-elderly group: median TTF, 21.8 months (95% CI: 18.2–24.6); HR for the elderly against the non-elderly: 1.46 (95% CI: 1.20–1.77), p < 0.001].” Correction: “elderly group: median TTF, 14.0 months (95% CI: 10.7–16.0);” Once again, the authors would like to sincerely apologize for any inconvenience caused; we thank you for the opportunity to submit this corrigendum.

Original language	English
Article number	107450
Journal	Lung Cancer
Volume	188
DOIs	https://doi.org/10.1016/j.lungcan.2023.107450
Publication status	Published - 02-2024

All Science Journal Classification (ASJC) codes

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.lungcan.2023.107450

Fingerprint

Dive into the research topics of 'Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426))'. Together they form a unique fingerprint.

Cite this

Sakata, Y., Saito, G., Sakata, S., Oya, Y., Tamiya, M., Suzuki, H., Shibaki, R., Okada, A., Yokoyama, T., Matsumoto, H., Otsuki, T., Sato, Y., Junji, U., Tsukita, Y., Inaba, M., Ikeda, H., Arai, D., Maruyama, H., Hara, S., ... Sakagami, T. (2024). Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426)). Lung Cancer, 188, Article 107450. https://doi.org/10.1016/j.lungcan.2023.107450

Sakata, Yoshihiko ; Saito, Go ; Sakata, Shinya et al. / Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426)). In: Lung Cancer. 2024 ; Vol. 188.

@article{2d538eece07f42d6922f11e24e6fa809,

title = "Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426))",

abstract = "The authors sincerely apologize for the errors; we have now corrected these errors. 1. Highlights Section: Error: “Median progression-free survival was shorter in the elderly than in the non-elderly.” Correction: “Time to treatment failure was shorter in the elderly than in the non-elderly.” 2. Abstract's Result Section: Error: “the time to treatment failure (TTF) was significantly shorter in the elderly than in the non-elderly [elderly group: median TTF, 14.0 months (95% CI: 0.98–1.50); non-elderly group: median TTF, 21.8 months (95% CI: 18.2–24.6); HR for the elderly against the non-elderly: 1.46 (95% CI: 1.20–1.77), p < 0.001].” Correction: “elderly group: median TTF, 14.0 months (95% CI: 10.7–16.0);” Once again, the authors would like to sincerely apologize for any inconvenience caused; we thank you for the opportunity to submit this corrigendum.",

author = "Yoshihiko Sakata and Go Saito and Shinya Sakata and Yuko Oya and Motohiro Tamiya and Hidekazu Suzuki and Ryota Shibaki and Asuka Okada and Toshihide Yokoyama and Hirotaka Matsumoto and Taiichiro Otsuki and Yuki Sato and Uchida Junji and Yoko Tsukita and Megumi Inaba and Hideki Ikeda and Daisuke Arai and Hirotaka Maruyama and Satoshi Hara and Shinsuke Tsumura and Jun Morinaga and Takuro Sakagami",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier B.V.",

year = "2024",

month = feb,

doi = "10.1016/j.lungcan.2023.107450",

language = "English",

volume = "188",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

}

Sakata, Y, Saito, G, Sakata, S, Oya, Y, Tamiya, M, Suzuki, H, Shibaki, R, Okada, A, Yokoyama, T, Matsumoto, H, Otsuki, T, Sato, Y, Junji, U, Tsukita, Y, Inaba, M, Ikeda, H, Arai, D, Maruyama, H, Hara, S, Tsumura, S, Morinaga, J & Sakagami, T 2024, 'Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426))', Lung Cancer, vol. 188, 107450. https://doi.org/10.1016/j.lungcan.2023.107450

Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426)). / Sakata, Yoshihiko; Saito, Go; Sakata, Shinya et al.
In: Lung Cancer, Vol. 188, 107450, 02.2024.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426))

AU - Sakata, Yoshihiko

AU - Saito, Go

AU - Sakata, Shinya

AU - Oya, Yuko

AU - Tamiya, Motohiro

AU - Suzuki, Hidekazu

AU - Shibaki, Ryota

AU - Okada, Asuka

AU - Yokoyama, Toshihide

AU - Matsumoto, Hirotaka

AU - Otsuki, Taiichiro

AU - Sato, Yuki

AU - Junji, Uchida

AU - Tsukita, Yoko

AU - Inaba, Megumi

AU - Ikeda, Hideki

AU - Arai, Daisuke

AU - Maruyama, Hirotaka

AU - Hara, Satoshi

AU - Tsumura, Shinsuke

AU - Morinaga, Jun

AU - Sakagami, Takuro

PY - 2024/2

Y1 - 2024/2

N2 - The authors sincerely apologize for the errors; we have now corrected these errors. 1. Highlights Section: Error: “Median progression-free survival was shorter in the elderly than in the non-elderly.” Correction: “Time to treatment failure was shorter in the elderly than in the non-elderly.” 2. Abstract's Result Section: Error: “the time to treatment failure (TTF) was significantly shorter in the elderly than in the non-elderly [elderly group: median TTF, 14.0 months (95% CI: 0.98–1.50); non-elderly group: median TTF, 21.8 months (95% CI: 18.2–24.6); HR for the elderly against the non-elderly: 1.46 (95% CI: 1.20–1.77), p < 0.001].” Correction: “elderly group: median TTF, 14.0 months (95% CI: 10.7–16.0);” Once again, the authors would like to sincerely apologize for any inconvenience caused; we thank you for the opportunity to submit this corrigendum.

AB - The authors sincerely apologize for the errors; we have now corrected these errors. 1. Highlights Section: Error: “Median progression-free survival was shorter in the elderly than in the non-elderly.” Correction: “Time to treatment failure was shorter in the elderly than in the non-elderly.” 2. Abstract's Result Section: Error: “the time to treatment failure (TTF) was significantly shorter in the elderly than in the non-elderly [elderly group: median TTF, 14.0 months (95% CI: 0.98–1.50); non-elderly group: median TTF, 21.8 months (95% CI: 18.2–24.6); HR for the elderly against the non-elderly: 1.46 (95% CI: 1.20–1.77), p < 0.001].” Correction: “elderly group: median TTF, 14.0 months (95% CI: 10.7–16.0);” Once again, the authors would like to sincerely apologize for any inconvenience caused; we thank you for the opportunity to submit this corrigendum.

UR - http://www.scopus.com/inward/record.url?scp=85181238201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85181238201&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2023.107450

DO - 10.1016/j.lungcan.2023.107450

M3 - Comment/debate

C2 - 38160082

AN - SCOPUS:85181238201

SN - 0169-5002

VL - 188

JO - Lung Cancer

JF - Lung Cancer

M1 - 107450

ER -

Sakata Y, Saito G, Sakata S, Oya Y, Tamiya M, Suzuki H et al. Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426)). Lung Cancer. 2024 Feb;188:107450. doi: 10.1016/j.lungcan.2023.107450

Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426))

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this